IP Library › Granted Patent US 10,336,812
Granted Patent B2
US 10,336,812 · App. 15/586,463 · Granted Jul 2, 2019

GDF15 fusion proteins and uses thereof

Inventors: Anthony Armstrong (Lawrence Township, NJ); Judith Ann Connor (Vista, CA); Jennifer Furman (San Diego, CA); Chichi Huang (Malvern, PA); Michael J. Hunter (Santee, PA); Xiefan Lin-Schmidt (Ambler, PA); Serena Nelson (San Diego, CA); Shamina Rangwala (Furlong, PA); Shannon Mullican (Philadelphia, PA); Jose Antonio Chavez (Warrington, PA)
Assignee: Janssen Biotech, Inc.
C07K14/765A61K38/16A61K38/17A61K38/18A61K38/1875A61K38/19C07K14/435C07K14/46C07K14/47C07K14/475C07K14/51C12N5/12C12N15/00C12N15/09C12N15/11C12N15/62C12N15/63A61K38/00C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,336,812
App. No.
15/586,463
Granted
Jul 2, 2019
Kind
B2
Abstract

Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.

Claims (26)

1. A fusion protein comprising:

a. the amino acid sequence of SEQ ID NO: 2;

b. a linker having a length of 35-48 amino acids and comprising the amino acid sequence of (GGGGS)n, wherein n is 7 or 8 (SEQ ID NO: 42 or 43); and

c. a truncated GDF15 consisting of the amino acid sequence of SEQ ID NO: 8;

wherein the fusion protein is arranged from N-terminus to C-terminus in the order (a)-(b)-(c), and the C-terminus of the amino acid sequence of SEQ ID NO: 2 is fused to the N-terminus of the truncated GDF15 through the linker.

2. The fusion protein of claim 1 , wherein the linker comprises the sequence (GGGGS)n, wherein n is 8 (SEQ ID NO: 43).

3. A fusion protein of claim 1 , wherein the linker consists of the amino acid sequence of SEQ ID NO: 12.

4. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein of claim 1 .

5. The isolated nucleic acid molecule of claim 4 comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 97-99.

6. A vector comprising a nucleic acid molecule encoding the fusion protein of claim 1 .

7. The vector of claim 6 comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 97-99.

8. A host cell comprising a nucleic acid molecule encoding the fusion protein of claim 1 .

9. A method of producing the fusion protein of claim 1 , comprising:

(1) culturing a host cell comprising a nucleic acid molecule encoding the fusion protein under a condition that the fusion protein is produced; and

(2) recovering the fusion protein produced by the host cell.

10. A pharmaceutical composition comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier.

11. A fusion protein comprising the amino acid sequence of SEQ ID NO: 92.

12. A pharmaceutical composition comprising the fusion protein of claim 11 and a pharmaceutically acceptable carrier.

13. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein of claim 11 .

14. The isolated nucleic acid molecule of claim 13 , comprising the nucleotide sequence of SEQ ID NO: 95.

15. A vector comprising a nucleic acid molecule encoding the fusion protein of claim 11 .

16. A host cell comprising a nucleic acid molecule encoding the fusion protein of claim 11 .

17. A method of producing the fusion protein of claim 11 , comprising:

(1) culturing a host cell comprising a nucleic acid molecule encoding the fusion protein under a condition that the fusion protein is produced; and

(2) recovering the fusion protein produced by the host cell.

18. The isolated nucleic acid molecule of claim 13 , comprising the nucleotide sequence of SEQ ID NO: 110.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2021
From: JANSSEN BIOTECH, INC.
To: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Reel/Frame 058079/0437 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2017
From: ARMSTRONG, ANTHONY; CONNOR, JUDITH ANN; FURMAN, JENNIFER; HUANG, CHICHI; HUNTER, MICHAEL J.; LIN-SCHMIDT, XIEFAN; NELSON, SERENA; RANGWALA, SHAMINA; MULLICAN, SHANNON; CHAVEZ, JOSE ANTONIO
To: JANSSEN BIOTECH, INC.
Reel/Frame 042487/0918 →
Continuity (2)
Provisional Application 62333886 · May 10, 2016
Related Publication 20170327560A1 · Nov 16, 2017
Cited By (2)
US 12,275,770 US 12,544,427